PMID- 37706062
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230916
IS  - 1178-7031 (Print)
IS  - 1178-7031 (Electronic)
IS  - 1178-7031 (Linking)
VI  - 16
DP  - 2023
TI  - Potential Mechanism of Fatigue Induction and Its Management by JAK Inhibitors in 
      Inflammatory Rheumatic Diseases.
PG  - 3949-3965
LID - 10.2147/JIR.S414739 [doi]
AB  - It is well known that fatigue is a highly disabling symptom commonly observed in 
      inflammatory rheumatic diseases (IRDs). Fatigue is strongly associated with a 
      poor quality of life and seems to be an independent predictor of job loss and 
      disability in patients with different rheumatic diseases. Although the 
      pathogenesis of fatigue remains unclear, indirect data suggest the cooperation of 
      the immune system, the central and autonomic nervous system, and the 
      neuroendocrine system in the induction and sustainment of fatigue in chronic 
      diseases. Fatigue does not correspond with disease activity and its mechanism in 
      IRDs. It is suggested that it may change over time and vary between individuals. 
      Abnormal production of pro-inflammatory cytokines such as interleukin-6 (IL-6), 
      interferons (IFNs), granulocyte-macrophage colony-stimulating factor (GM-CSF), 
      TNF, IL-15, IL-17 play a role in both IRDs and subsequent fatigue development. 
      Some of these cytokines such as IL-6, IFNs, GM-CSF, and common gamma-chain 
      cytokines (IL-15, IL-2, and IL-7) activate the Janus Kinases (JAKs) family of 
      intracellular tyrosine kinases. Therapy blocking JAKs (JAK inhibitors - JAKi) has 
      been recently proven to be an effective approach for IRDs treatment, more 
      efficient in pain reduction than anti-TNF. Therefore, the administration of JAKi 
      to IRDs patients experiencing fatigue may find rational implications as a 
      therapeutic modulator not only of disease inflammatory symptoms but also fatigue 
      with its components like pain and neuropsychiatric features as well. In this 
      review, we demonstrate the latest information on the mechanisms of fatigue in 
      rheumatic diseases and the potential effect of JAKi on fatigue reduction.
CI  - (c) 2023 Felis-Giemza et al.
FAU - Felis-Giemza, Anna
AU  - Felis-Giemza A
AUID- ORCID: 0000-0003-2198-8225
AD  - Biologic Therapy Center, National Institute of Geriatrics, Rheumatology, and 
      Rehabilitation (NIGRiR), Warsaw, Poland.
FAU - Massalska, Magdalena
AU  - Massalska M
AUID- ORCID: 0000-0002-2146-1100
AD  - Department of Pathophysiology and Immunology, National Institute of Geriatrics, 
      Rheumatology, and Rehabilitation (NIGRiR), Warsaw, Poland.
FAU - Roszkowski, Leszek
AU  - Roszkowski L
AD  - Department of Outpatient Clinics, National Institute of Geriatrics, Rheumatology, 
      and Rehabilitation (NIGRiR), Warsaw, Poland.
FAU - Romanowska-Prochnicka, Katarzyna
AU  - Romanowska-Prochnicka K
AUID- ORCID: 0000-0003-1326-2600
AD  - Department of Biophysics, Physiology and Pathophysiology, Faculty of Health 
      Sciences, Warsaw Medical University, Warsaw, Poland.
FAU - Ciechomska, Marzena
AU  - Ciechomska M
AUID- ORCID: 0000-0002-0961-6130
AD  - Department of Pathophysiology and Immunology, National Institute of Geriatrics, 
      Rheumatology, and Rehabilitation (NIGRiR), Warsaw, Poland.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20230908
PL  - New Zealand
TA  - J Inflamm Res
JT  - Journal of inflammation research
JID - 101512684
PMC - PMC10497048
OTO - NOTNLM
OT  - JAK inhibitors
OT  - baricitinib
OT  - fatigue
OT  - patient-reported outcomes
OT  - tofacitinib
OT  - upadacitinib
COIS- The authors report no conflicts of interest in this work.
EDAT- 2023/09/14 06:42
MHDA- 2023/09/14 06:43
PMCR- 2023/09/08
CRDT- 2023/09/14 04:13
PHST- 2023/03/28 00:00 [received]
PHST- 2023/07/27 00:00 [accepted]
PHST- 2023/09/14 06:43 [medline]
PHST- 2023/09/14 06:42 [pubmed]
PHST- 2023/09/14 04:13 [entrez]
PHST- 2023/09/08 00:00 [pmc-release]
AID - 414739 [pii]
AID - 10.2147/JIR.S414739 [doi]
PST - epublish
SO  - J Inflamm Res. 2023 Sep 8;16:3949-3965. doi: 10.2147/JIR.S414739. eCollection 
      2023.